By Fineline Cube Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its innovative antibody-drug conjugate (ADC), SHR-4375 injection, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer. The tissue factor (TF)-targeting ADC is independently developed by Hengrui and currently in Phase 2 clinical trials in China, representing a significant advancement in addressing one of oncology’s most challenging malignancies.
Development Overview
| Item | Detail |
|---|---|
| Sponsor | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) |
| Drug Candidate | SHR-4375 injection |
| Drug Class | Tissue factor (TF)-targeting antibody-drug conjugate (ADC) |
| Indication | Pancreatic cancer |
| Regulatory Milestone | FDA Orphan Drug Designation (ODD) |
| Milestone Date | 28 Jul 2026 |
| Clinical Stage (China) | Phase 2 |
| Development Status | Independently developed by Hengrui Pharma |
Drug Profile & Mechanism of Action
- Target: Tissue Factor (TF) expressed on tumor cell surface
- Antibody Moiety: Specifically binds to TF on pancreatic cancer cells
- Internalization: Endocytosis-mediated uptake into target tumor cells
- Payload Release: Intracellular cleavage releases cytotoxic payload
- Primary Effect: Direct induction of tumor cell apoptosis
- Bystander Effect: Released toxin diffuses to extracellular space, killing adjacent TF-negative tumor cells
- Therapeutic Innovation: Dual killing mechanism addresses tumor heterogeneity common in pancreatic cancer
Clinical Context – Pancreatic Cancer
| Parameter | Clinical Significance |
|---|---|
| 5-Year Survival Rate | <10% (one of the lowest among solid tumors) |
| Treatment Challenges | Dense stromal barrier, immunosuppressive microenvironment, late diagnosis |
| Current Standard | Limited options with modest survival benefits |
| Unmet Need | High priority for novel targeted therapies with improved efficacy |
| Orphan Drug Rationale | Affects fewer than 200,000 patients annually in the US |
The ODD recognizes both the severity of pancreatic cancer and the potential of SHR-4375 to address critical unmet needs in this patient population.
Market Impact & Strategic Implications
- Orphan Drug Benefits: ODD provides 7 years of market exclusivity in the US upon approval, plus tax credits, fee waivers, and protocol assistance
- Pancreatic Cancer Market: Despite low prevalence, high unmet need supports premium pricing; global pancreatic cancer therapeutics market projected to reach $3.5 billion by 2030
- ADC Competitive Position: Positions Hengrui among elite developers of next-generation ADCs with bystander effects, joining companies like Daiichi Sankyo and ImmunoGen
- Global Development Strategy: FDA ODD validates international potential and may accelerate regulatory pathways in other major markets
- China-US Bridge: Demonstrates successful navigation of both Chinese and US regulatory frameworks, enhancing Hengrui’s global credibility
- Platform Validation: Success of SHR-4375 could validate Hengrui’s ADC platform for additional TF-expressing solid tumors
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory pathways, and commercial potential for SHR-4375. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and market acceptance.-Fineline Info & Tech